Arovella Therapeutics Limited

ASX:ALA Stock Report

Market Cap: AU$184.0m

Arovella Therapeutics Past Earnings Performance

Past criteria checks 0/6

Arovella Therapeutics's earnings have been declining at an average annual rate of -6.8%, while the Pharmaceuticals industry saw earnings growing at 35.6% annually. Revenues have been growing at an average rate of 10.2% per year.

Key information

-6.8%

Earnings growth rate

46.4%

EPS growth rate

Pharmaceuticals Industry Growth31.2%
Revenue growth rate10.2%
Return on equity-326.4%
Net Margin-519.2%
Last Earnings Update31 Dec 2023

Recent past performance updates

Recent updates

We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Jul 01
We're Hopeful That Suda Pharmaceuticals (ASX:SUD) Will Use Its Cash Wisely

Revenue & Expenses Breakdown

How Arovella Therapeutics makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

ASX:ALA Revenue, expenses and earnings (AUD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
31 Dec 232-1036
30 Sep 232-1035
30 Jun 231-1024
31 Mar 232-924
31 Dec 222-924
30 Sep 221-923
30 Jun 220-923
31 Mar 220-822
31 Dec 211-721
30 Sep 211-621
30 Jun 211-511
31 Mar 211-510
31 Dec 201210
30 Sep 201-110
30 Jun 201-410
31 Mar 201-1220
31 Dec 191-1510
30 Sep 191-1110
30 Jun 191-810
31 Mar 191-610
31 Dec 181-520
30 Sep 181-520
30 Jun 180-620
31 Mar 185-420
31 Dec 171-320
30 Sep 171-220
30 Jun 171-110
31 Mar 174-120
31 Dec 163-120
30 Sep 165-220
30 Jun 166-230
31 Mar 166-320
31 Dec 156-320
30 Sep 156-320
30 Jun 156-330
31 Mar 156-430
31 Dec 146-430
30 Sep 147-330
30 Jun 149-220
31 Mar 148-220
31 Dec 138-120
30 Sep 136-110

Quality Earnings: ALA is currently unprofitable.

Growing Profit Margin: ALA is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: ALA is unprofitable, and losses have increased over the past 5 years at a rate of 6.8% per year.

Accelerating Growth: Unable to compare ALA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ALA is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.2%).


Return on Equity

High ROE: ALA has a negative Return on Equity (-326.43%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.